atorvastatin has been researched along with Adenocarcinoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fullerton, DA; Gergen, AK; Halpern, AL; Kohtz, PD; Meng, X; Weyant, MJ; White, AM | 1 |
| Albertsson, M; Holmqvist, A; Kotti, A; Sun, XF | 1 |
| Bang, S; Chung, MJ; Lee, HJ; Lee, HS; Lee, SH; Park, JY; Park, SW; Song, SY | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| DeCastro, A; Janakiram, NB; Lee, HJ; Paul, S; Rao, CV; Reddy, BS; Simi, B; Smolarek, AK; So, JY; Steele, V; Suh, N; Wang, CX | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
6 other study(ies) available for atorvastatin and Adenocarcinoma
| Article | Year |
|---|---|
Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Animals; Atorvastatin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Random Allocation; Signal Transduction; Simvastatin; Toll-Like Receptor 4; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Protective Factors; Rectal Neoplasms; Retrospective Studies; Simvastatin; Survival Rate; Sweden | 2019 |
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients.
Topics: Adenocarcinoma; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Simvastatin; Survival Rate; Time Factors | 2016 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cyclin D1; eIF-2 Kinase; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunoenzyme Techniques; Interleukin-4; Male; Naproxen; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Inbred F344; Signal Transduction; Sulindac; Tumor Necrosis Factor-alpha | 2011 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |